Asymchem Laboratories Tianjin CoASLTY 69 Net Current Asset Value is $1.80 as of Mar. 2026, which is 87% below its 10-year median of 13.92. GuruFocus rates ASLTY with a GF Score™ of 69/100 and a GF Value™ of $3.90 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 946 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks worse than 61.84% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for Asymchem Laboratories Tianjin Co's Net Current Asset Value or its related term are showing as below:
ASLTY'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.96 Med: 13.92 Max: 56.75
Current: 6.64
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Asymchem Laboratories Tianjin Co was 56.75. The lowest was 2.96. And the median was 13.92.
ASLTY's Price-to-Net-Current-Asset-Value is ranked worse than 61.84% of 946
companies
in the Biotechnology industry
Industry Median: 4.87
vs ASLTY: 6.64
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Asymchem Laboratories Tianjin Co Net Current Asset Value Related Terms
Asymchem Laboratories Tianjin Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co Net Current Asset Value Chart
ASLTY vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.80 mean?
Asymchem Laboratories Tianjin Co (ASLTY) has a Net Current Asset Value of $1.80 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Asymchem Laboratories Tianjin Co and its competitors. This is 87% below median its historical median of 13.92. Over the past decade, Asymchem Laboratories Tianjin Co's Net Current Asset Value has ranged from 2.96 to 56.75. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #585 out of 946 companies in the Biotechnology industry, placing it in the top 61.8%.
Is Asymchem Laboratories Tianjin Co's Net Current Asset Value too high?
Asymchem Laboratories Tianjin Co's current Net Current Asset Value of $1.80 is 87% below median its 10-year median of 13.92. Over the past 10 years, this metric has ranged from a low of 2.96 to a high of 56.75. The Biotechnology industry median Net Current Asset Value is 4.87. Asymchem Laboratories Tianjin Co's value of $1.80 is 63% below this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #585 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #585 out of 946 companies for Net Current Asset Value. This places Asymchem Laboratories Tianjin Co in the lower half of its industry. The industry median Net Current Asset Value is 4.87. Asymchem Laboratories Tianjin Co's value of $1.80 is 63% below this benchmark. Historically, Asymchem Laboratories Tianjin Co's own Net Current Asset Value has ranged from 2.96 to 56.75 over the past decade. While the company's 10-year median is 13.92 vs. the industry median of 4.87, Asymchem Laboratories Tianjin Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.87, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current Net Current Asset Value of $1.80 is 63% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Asymchem Laboratories Tianjin Co and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current Net Current Asset Value is $1.80, which is 87% below median its own 10-year median of 13.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.90, compared to a current price of $6.37 — trading 63.3% above its estimated fair value. The current Net Current Asset Value is $1.80, which is 87% below median its 10-year median of 13.92 and 63% below the Biotechnology industry median of 4.87. Asymchem Laboratories Tianjin Co's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current Net Current Asset Value is $1.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $6.37 is trading 63.3% above its estimated GF Value™ of $3.90.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
Net Current Asset Value: $1.80 (87% below median its 10-year median of 13.92)
GF Value™: $3.90 vs. price of $6.37 (63.3% above fair value)
Industry Position: 63% below the Biotechnology median (#585 of 946)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
69GF Score
Get the complete analysis for ASLTY
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
